CSL Behring has paid out $91 million upfront for biotech Calimmune and gains a preclinical asset for sickle cell disease and β-thalassemia, adding to its blood disease pipeline.
The biotech is working on ex vivo hematopoietic stem cell (HSC) gene therapy, with R&D facilities in Pasadena, California, and Sydney, New South Wales, Australia, that will now transfer over to CSL.
For its $91 million, and $300-plus in biobucks, CSL also gets two platform technologies, Select+ and Cytegrity, which are “designed to address some of the major challenges currently associated with the commercialization of stem cell therapy,” according to the company.
This includes the ability to manufacture consistent, high-quality products and to improve engraftment, efficacy and tolerability, it said in a statement. Both technologies have “broad applications in ex vivo stem cell gene therapy.”
“Calimmune shares in our promise and focus to improve the lives of patients with rare and serious medical conditions,” said CSL CEO and managing director Paul Perreault. “The acquisition represents another important step in the execution of our strategy for sustainable growth. Calimmune’s scientific accomplishments are impressive.”
“The team has built a robust technology platform, and designed a promising HSC gene therapy candidate, CAL-H, which strongly aligns with our longer-term strategic goals, and complements our core competencies and areas of therapeutic focus,” Perreault added.“ While Calimmune is still in the early stages, we believe that our combined strengths have tremendous potential to change treatment paradigms, and most importantly, significantly improve the lives of our patients.”
Calimmune’s chief, Louis Breton, added: “We are excited to become part of CSL Behring. They are an established global industry leader in protein-replacement therapies and have a proven track record of driving innovations through the development pipeline and delivering differentiated products to the global marketplace. Together, we are well-positioned to take our achievements to the next level.”
By Ben Adams
Source: Fierce Biotech
The United Arab Emirates (UAE) Ministry of Health and Prevention (MoHAP) has established a partnership with Novo Nordisk Pharma Gulf focusing on the creation of a national scientific guide for obesity management and weight control. The collaboration also aims to enhance public awareness of cardiovascular diseases and their complications.
Pharma giant Eli Lilly is teaming up with Haya Therapeutics in a $1bn deal to find multiple regulatory-genome-derived RNA-based drug targets, as it eyes up new targets in obesity. Under the deal, the companies will use Haya’s proprietary regulatory genome discovery platform to identify and validate long non-coding RNA (lncRNA) targets for developing potential treatments for obesity and related metabolic disorders.
The sale includes custom formulation and contract manufacturing capabilities for the nutrition market from the production facilities in New Jersey and Utah in the United States, and Tamaulipas, Mexico. Financial terms of the transaction were not disclosed.
